Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
- Cancer
- Concussions
- CRISPR
- Drug Pricing
- End of Life
- Health Disparities
- Immigration
- Opioids
- Trump
- Women’s Health
- Zika
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Business

Biotech, pharma, and money in science

Adam's Take

With its silence on key questions, Omeros raises doubts about its rare disease drug

By Adam Feuerstein

Biotech

Ironwood wins FDA approval for combination gout treatment

By Jonathan Saltzman

advertisement

In the Know

Biotech recruiter’s advice to women: You don’t have to be perfect

By Meghana Keshavan

advertisement

Business

A veteran biopharma executive tries to fund his own product — and sees firsthand how hard it is

By Rebecca Robbins

Adam's Take

Aerie’s drug manufacturing risk reliever; September biotech events on tap

By Adam Feuerstein

Adam's Take

FDA approval of Aerie Pharma glaucoma drug jeopardized by problems outside its control

By Adam Feuerstein

Politics

Who gets all that biopharma lobbying money?

By Charles Piller

advertisement

Business

J&J CEO to stay on Trump’s advisory group amid executive exodus

By Damian Garde and Rebecca Robbins

advertisement

Pharmalot

Pharmalittle: N.H. city considers the latest opioid lawsuit; drug industry middlemen criticized, again

By Rebecca Robbins

Adam's Take

Will the Trump-Frazier tiff set off another White House attack on drug prices?

By Adam Feuerstein

Politics

Merck CEO quits Trump panel in ‘stand against violence and extremism’

By Damian Garde

Pharma

With deadlines looming, pharma companies look to tighten drug security

By Jonathan Wosen

Business

As losses mount, Soon-Shiong’s NantHealth to lay off dozens, reduce headcount by 300

By Rebecca Robbins

Business

Mylan, like other generic drugmakers, feels the pricing pain

By Associated Press

In the Lab

How a ‘Velcro’ chip that traps alien DNA could improve prenatal testing

By Kate Sheridan

Pharma

High drug prices loom large at gathering of state legislators

By Rebecca Robbins

Biotech

MyoKardia drug improves blood flow in patients with serious, inherited form of heart disease

By Adam Feuerstein

Health

FDA OKs new drug to treat all forms of hepatitis C

By Associated Press

Adam's Take

Ziopharm claims FDA loves its brain cancer gene therapy, so why is the Phase 3 study taking so long to start?

By Adam Feuerstein

Health

Can a genetic test really boost your odds of becoming pregnant?

By Rebecca Robbins

Adam's Take

We need to discard the ratty T-shirts of biotech. Anyone up for a Venture Capital Death Panel?

By Adam Feuerstein

Adam's Take

The biotech mailbag: Your questions answered on Clovis Oncology, CytRx, Brainstorm Therapeutics, and more

By Adam Feuerstein

Pharma

AstraZeneca lung cancer immunotherapy trial failure sends shares plunging

By Adam Feuerstein

Adam's Take

Strong growth in sales of colon cancer test dents the pessimism of Exact Sciences shorts

By Adam Feuerstein

Pharma

Pharma companies flock to new drug production approach that promises big savings

By Jonathan Wosen

Business

Biogen is shopping for neuroscience drug assets. Here’s a target list

By Adam Feuerstein

Pharma

These 10 drugs each rang up more than $4 billion in U.S. sales last year

Adam's Take

Merck: Keytruda trial comes up short in head and neck cancer, but FDA approval stays

By Adam Feuerstein

Business

Three storylines to watch from Biogen earnings & Dynavax tries again to win hepatitis B vaccine approval

By Adam Feuerstein

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT